2026年,这22款药物值得关注

药智网
Feb 12

GLP-1类药物能否从减重用药进阶为慢病解决方案?神经调控、基因编辑等高风险前沿领域,是否值得持续投入资源深耕布局?近期,国际行业媒体FirstWord Pharma发布《Spotlight On:The drugs that will shape 2026》榜单,基于此笔者梳理出22款有望在2026年及未来重塑疾病治疗逻辑的标杆药物。这些药物的核心价值与临床潜力,或许能给上面的议题给出线索和答案...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10